MiNK Therapeutics (INKT) Institutional Ownership → Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad) Free INKT Stock Alerts $0.96 -0.02 (-2.03%) (As of 06/7/2024 ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for MiNK Therapeutics (NASDAQ:INKT)CurrentInstitutional OwnershipPercentage2.87%Number ofInstitutional Buyers(last 12 months)3TotalInstitutional Inflows(last 12 months)$818.08KNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$143.80K Get INKT Insider Trade Alerts Want to know when executives and insiders are buying or selling MiNK Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data INKT Institutional Buying and Selling by Quarter Ad Paradigm PressAfter Conviction, More Bad News for TrumpAs a former advisor to the CIA, the Pentagon and the White House… I feel it’s my duty to warn you about this coming election meltdown.Click here to see the details because this coming election meltdown could trigger… MiNK Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/14/2023 Oracle Investment Management Inc.36,898$41K0.0%-26.9%0.107% 8/14/2023 Oracle Investment Management Inc.50,461$106K0.1%N/A0.146% 8/14/2023 Deep Track Capital LP324,867$682K0.0%N/A0.941% 8/11/2023 Artal Group S.A.228,216$479K0.0%-21.2%0.663% 7/27/2023 Virtu Financial LLC14,232$30K0.0%N/A0.041% 2/10/2023 StoneX Group Inc.17,821$47K0.0%N/A0.053% 11/4/2022First Republic Investment Management Inc.81,500$172K0.0%N/A0.243% 2/15/2022 Sofinnova Investments Inc.345,499$1.54M0.1%N/A1.031% (Data available from 1/1/2016 forward) INKT Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of INKT shares? During the previous two years, the following institutional investors and hedge funds held shares of MiNK Therapeutics shares: Deep Track Capital LP ($682K), Artal Group S.A. ($479K), First Republic Investment Management Inc. ($172K), StoneX Group Inc. ($47K), and Oracle Investment Management Inc. ($41K), Virtu Financial LLC ($30K).Learn more on INKT's institutional investors. What percentage of MiNK Therapeutics stock is owned by institutional investors? 2.87% of MiNK Therapeutics stock is owned by institutional investors. Learn more on INKT's institutional investor holdings. Which institutional investors have been buying MiNK Therapeutics stock? The following institutional investors have purchased MiNK Therapeutics stock in the last 24 months: Deep Track Capital LP ($324.87K), First Republic Investment Management Inc. ($81.50K), Oracle Investment Management Inc. ($50.46K), StoneX Group Inc. ($17.82K), and Virtu Financial LLC ($14.23K). How much institutional buying is happening at MiNK Therapeutics? Institutional investors have bought a total of 488,881 shares in the last 24 months. This purchase volume represents approximately $1.04M in transactions. Which MiNK Therapeutics major shareholders have been selling company stock? The following institutional investors have sold MiNK Therapeutics stock in the last 24 months: Artal Group S.A. ($61.37K), and Oracle Investment Management Inc. ($13.56K). How much institutional selling is happening at MiNK Therapeutics? Institutional investors have sold a total of 74,935 shares in the last 24 months. This volume of shares sold represents approximately $143.80K in transactions. Related Companies: Celularity Institutional Ownership Adicet Bio Institutional Ownership Cardiff Oncology Institutional Ownership aTyr Pharma Institutional Ownership Sangamo Therapeutics Institutional Ownership DBV Technologies Institutional Ownership bluebird bio Institutional Ownership Omega Therapeutics Institutional Ownership Athira Pharma Institutional Ownership Vigil Neuroscience Institutional Ownership This page (NASDAQ:INKT) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.